News Headlines Article

Experimental lung cancer vaccine lands Berkeley company potential $817M deal
San Francisco Business Times

Tiny Aduro BioTech Inc.’s experimental cancer vaccine has come up big again, landing a potential $817 million deal with Johnson & Johnson’s Janssen Biotech unit around lung cancer, the companies said Thursday.

Berkeley’s Aduro and Janssen in May signed a potential $365 million deal centered on the same technology to treat prostate cancer. This latest deal gives Aduro $30 million upfront and the ability to receive more if the lung cancer treatment, called ADU-214, hits certain development, regulatory and commercial milestones.